Development of a cross-protective common cold coronavirus vaccine

Area of Science:

• * Virology
• * Immunology
• * Vaccine Development

Background:

• * Common cold coronaviruses (e.g., OC43, HKU1) cause mild illness in healthy individuals but severe disease in high-risk groups.
• * No clinically approved vaccines currently exist for common cold coronaviruses.
• * Vulnerable populations, including immunocompromised individuals and older adults, are at significant risk.

Purpose of the Study:

• * To develop and evaluate an mRNA vaccine against the OC43 coronavirus.
• * To assess the vaccine's efficacy in protecting against homologous and heterologous coronavirus challenges.
• * To explore the potential for broad-spectrum protection against embecoviruses.

Main Methods:

• * Development of an mRNA vaccine encoding a stabilized spike protein from OC43 coronavirus.
• * Testing vaccine efficacy in C57BL/6 mouse models.
• * Evaluation of immune responses, including specific and cross-reactive antibody and cellular immunity.
• * Challenge studies using OC43 and mouse hepatitis virus (MHV-A59).

Main Results:

• * The OC43 mRNA vaccine successfully elicited OC43-specific immune responses.
• * The vaccine induced cross-reactive immunity against other embecoviruses, including HKU1 and MHV-A59.
• * Vaccinated mice demonstrated protection against lethal OC43 infection and challenge with the distant embecovirus MHV-A59.

Conclusions:

• * An mRNA vaccine targeting the OC43 spike protein can provide protection against homologous and heterologous embecovirus infections.
• * This approach demonstrates the feasibility of developing a single vaccine for broad protection against multiple coronaviruses within the embecovirus subgenus.
• * Findings support the advancement of pan-coronavirus vaccine strategies.